Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...

As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has ...

Sales of Eli Lilly's lead drug, tirzepatide, which it markets as Zepbound for weight loss and Mounjaro for diabetes, leapt up to a combined $5.4 billion in the fourth quarter. That's some amazing ...

The endorsement comes in response to new clinical trial data from a competitor's weight loss drug, which Leerink believes reinforces the market potential for Eli Lilly's tirzepatide. The recent ...

The endorsement comes in response to new clinical trial data from a competitor's weight loss drug, which Leerink believes reinforces the market potential for Eli Lilly's tirzepatide. The recent Phase ...

assumptions regarding the performance of the diabetes drug tirzepatide in 2025 will be scrutinized, especially concerning international markets and the dynamics of access and stocking. Eli Lilly's ...

Eli Lilly and Company (NYSE:LLY) will increase its dividend from last year's comparable payment on the 10th of March to $1.50. This takes the annual payment to 0.8% of the current stock price ...